ENROTAS BH

Each ml contains:
Enrofloxacin. 200 mg
Bromhexine. 15 mg
Excipients. q.s.

Treatment of severe and complicated respiratory diseases (CCRD, CRD).
Management of infections where mucus accumulation hinders recovery.
Effective against Mycoplasma and other bacterial pathogens.
Used for respiratory signs associated with infectious bronchitis.
Control of bacterial diseases like Colibacillosis and Salmonellosis.

ENROTAS-BH provides dual action. Enrofloxacin is bactericidal, inhibiting bacterial DNA gyrase and Topoisomerase IV, preventing DNA replication and causing rapid cell death against a broad range of pathogens. Bromhexine acts as a mucolytic by decreasing the viscosity of respiratory secretions, breaking down mucopolysaccharide fibers. This dual action facilitates deeper antibiotic penetration into the respiratory tissues and clears airways, enhancing antibiotic efficacy, and improving breathing.

Dual action delivers antibiotic and mucus clearance in one dose.
Improved antibiotic access to the site of deep respiratory infection.
Clears airways, leading to easier breathing and improved oxygenation.
Broad-spectrum antibiotic coverage ensures effective bacterial control.
Convenient liquid form for easy mass medication via drinking water.

For oral administration
0.5 mL of ENROTAS-BH per 1 litre of drinking water.
Duration: Administer continuously for 3 to 5 days, or as directed by the attending veterinarian.
Note: In severe cases, the dosage can be increased up to 1.0 mL per 1 litre of water.

15 ml, 50 ml, 100 ml, 250 ml, 500 ml and 1000 ml HDPE Bottle

Oral Liquid